FAST
41
7
COP
36
2
APA
30
5
XRX
48
2
TRV
34
4
CNP
59
17
DRI
74
5
JWN
72
9
WM
53
2
BAX
38
2
WAT
55
11
IP
53
3
MRK
25
2
HSIC
42
2
CVX
25
14
NI
63
5
AA
27
5
ADT
12
2
DE
49
3
EMR
57
7
FAST
41
7
COP
36
2
APA
30
5
XRX
48
2
TRV
34
4
CNP
59
17
DRI
74
5
JWN
72
9
WM
53
2
BAX
38
2
WAT
55
11
IP
53
3
MRK
25
2
HSIC
42
2
CVX
25
14
NI
63
5
AA
27
5
ADT
12
2
DE
49
3
EMR
57
7
Financhill
Back

Halozyme Therapeutics 10K Form

Buy
51

HALO
Halozyme Therapeutics

Last Price:
$46.95
Seasonality Move:
7.09%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-07 10Q HALO/Halozyme Therapeutics Quarterly
2023-11-06 10Q HALO/Halozyme Therapeutics Quarterly
2023-08-08 10Q HALO/Halozyme Therapeutics Quarterly
2023-05-09 10Q HALO/Halozyme Therapeutics Quarterly
2022-11-08 10Q HALO/Halozyme Therapeutics Quarterly
2022-08-09 10Q HALO/Halozyme Therapeutics Quarterly

Receive HALO News And Ratings

See the #1 stock for the next 7 days that we like better than HALO

HALO Financial Statistics

Sales & Book Value

Annual Sales: $829.3M
Cash Flow: $113.9M
Price / Cash Flow: 15.52
Annual Sales: $3.56
Price / Book: 13.19

Profitability

EPS (TTM): 3.02000
Net Income (TTM): $392.5M
Gross Margin: $636.9M
Return on Equity: 156.62%
Return on Assets: 20.54%

Halozyme Therapeutics Earnings Forecast

Key Halozyme Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 23 years for HALO is 76.80%.
  • The Selling, General & Administrative Expenses for HALO have been equal to 17.99% of Gross Profit Margin.
  • The Research & Development expenses have been 9.21% of Revenue.
  • The Interest Expense is 6.66% of Operating Income.
  • The Net Earning history of HALO is 33.96% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 11 years.

Halozyme Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: HALO
CUSIP: 40637H
Website: halozyme.com

Debt

Debt-to-Equity Ratio: 3.32
Current Ratio: 10.36
Quick Ratio: 8.75

Price-to-Earnings

Trailing P/E Ratio: 22.35
Forward P/E Ratio: 10.02

HALO Technical Analysis vs Fundamental Analysis

Buy
51
Halozyme Therapeutics (HALO) is a Buy

Is Halozyme Therapeutics a Buy or a Sell?